

**European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome  
(EUROMENE)**

**COST action CA15111**

**Deliverable 9**

**Guidelines for usage of immunological biomarkers in ME/CFS diagnosis and  
therapy evaluation**

As a first step for developing biomarkers for clinical use a database of active biomarker research in Europe was established called the ME/CFS EUROMENE Biomarker Landscape project. In addition a survey was performed including all publications worldwide.

So far there is no single immune marker available for diagnostic use in ME/CFS. Heterogeneity of biomarker studies with different case definitions, low number of patients, lack of matched control groups, missing validation studies and potentially subgroup heterogeneity are possible reasons why no diagnostic biomarkers are available yet.

This search and strategies to improve biomarker development are reported in:

**Scheibenbogen C, Freitag H, Blanco J, Capelli E, Lacerda E, Authier J, Meeus M, Castro Marrero J, Nora-Krukke Z, Oltra E, Strand EB, Shikova E, Sekulic S, Murovska M. The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE. J Transl Med. 2017 Jul Review.**

<https://www.ncbi.nlm.nih.gov/pubmed/28747192>

